



ASX Announcement

18 February 2022

Atomo H1 FY22 Results Investor Briefing

SYDNEY Australia, 18 February 2022 – Atomo Diagnostics Limited (ASX: AT1) (**Atomo**) advises that it will be releasing its half yearly report for the period ended 31 December 2021 on, Monday, 21 February 2022, and invites investors to attend an online briefing to discuss the results on Tuesday, 22 February 2022 at 11:30 am (Sydney time).

During the briefing, Co-founder/Managing Director, John Kelly, and Chief Financial Officer, Will Souter, will discuss recent developments and talk to the Company's forward looking strategy. This will be followed by a Q+A session.

Participants can pre-register ahead of time via the following link:

https://us02web.zoom.us/webinar/register/WN_EdW3htbWTVS3vkZlahe_Zw

Once the registration form is completed, investors will receive a confirmation email with details on how to access the briefing. If you would like to ask a question during the briefing, please send your question ahead of the session to: george.kopsiaftis@irdepartment.com.au.

For more information, please contact:

Jane Lowe

IR Department

jane.lowe@irdepartment.com.au

Phone: +61 411 117 774

John Kelly

Atomo Diagnostics

john.kelly@atomodiagnostics.com

Phone: +61 401 922 279

This announcement was authorised by the Board of Directors.



About Atomo

Atomo is an Australian medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market. Atomo's patented devices simplify testing procedures and enhance usability for professional users and untrained self-testers. The Company has supply agreements in place for tests targeting infectious diseases including COVID-19, HIV, viral vs bacterial differentiation and female health. See more at www.atomodiagnosics.com.